Ocular Therapeutix Inc. Common Stock (OCUL)

FairStock Score: 30/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Ocular Therapeutix is not a Graham-style bargain in the ordinary sense. It sells DEXTENZA, an ophthalmic insert, and is developing AXPAXLI for retinal disease. But the reported record shows a business that is not yet self-supporting. In fiscal 2025, the year ended 2025-12-31, revenue was $52.0 million and net loss was $265.9 million, or $1.42 per diluted share. That loss widened from $193.5 million in fiscal 2024 and $80.7 million in fiscal 2023. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $13.5 million while net loss was $78.8 million, or $0.35 per diluted share. In fiscal Q1 2026, the quarter ended 2026-03-31, the net loss was $88.6 million. On the positive side, debt-to-equity is 0.15, and the Altman Z-Score is 4.22. But trailing free cash flow is negative $255.1 million, a -16.0% FCF yield, and ROE is -72.99%. Piotroski is 3/9, confirming weak fundamentals. At the 2026-10-13 close of $7.24, the market cap is $1.6 billion, price-to-book is 3.05, and the FairStock Score is 30/100. The P/E is negative at -5.17 because there are no earnings. The Lynch category is none, as it has lost money each of the last four years. Competitive strength may exist in its hydrogel platform, but I cannot see a durable moat from these numbers. The valuation rests on future pipeline success, not current cash generation. Without a margin of safety in the present business, this looks like speculation, not value. I would want evidence of commercial traction and controlled cash burn before calling it a sound investment.

In plain English: Ocular Therapeutix is a healthcare company that sells an eye treatment called DEXTENZA and is developing another eye therapy called AXPAXLI. The business looks weak today: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $13.5 million and it lost $78.8 million. The stock at $7.24 on 2026-10-13 does not look cheap compared with current numbers because there are no profits, even though it is near the low end of its past year's price range.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer